Daqing Wu to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Daqing Wu has written about Drug Resistance, Neoplasm.
Connection Strength
1.745
-
Zhao R, Ma X, Bai L, Li X, Mamouni K, Yang Y, Liu H, Danaher A, Cook N, Kucuk O, Hodges RS, Gera L, Wu D. Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. Neoplasia. 2021 12; 23(12):1261-1274.
Score: 0.602
-
Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 2021; 11(14):6873-6890.
Score: 0.581
-
Bai L, Li X, Ma X, Zhao R, Wu D. In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. Anticancer Res. 2020 Nov; 40(11):6051-6062.
Score: 0.561